Agenus Inc

Agenus Inc. is a publicly traded company headquartered in Lexington, Massachusetts. With a team of 338 employees, Agenus operates in the biotechnology sector, focusing on developing innovative solutions for cancer and infectious diseases. The company generated $100 million in revenue in its last fiscal year. Agenus specializes in immuno-oncology, utilizing a multifaceted approach to cancer immunotherapy. Their product pipeline encompasses a range of immunological agents, including antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics), and adjuvants (through SaponiQx). These solutions are designed to enhance the effectiveness of cancer immunotherapies and expand patient access to this groundbreaking treatment. Agenus distinguishes itself through its comprehensive portfolio of immunological agents and its commitment to combination therapies. By integrating diverse therapeutic modalities, the company aims to maximize treatment efficacy and target a broader range of cancers and infectious diseases. For more information about Agenus and its innovative work, visit their website at www.agenusbio.com.